Related content

Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT

By Ou Xueling   Cai Shaohui   Liu Peng   Zeng Jun   He Yuwen   Wu Xinyao   Du Jun  

Journal of Cancer Research and Clinical Oncology, Vol. 134, Iss. 5, 2008-05 ,pp. : 525-533

Springer Publishing Company

Access to resources Recommend Favorite

Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients

By            

International Journal of Oncology, Vol. 43, Iss. 1, 2013-01 ,pp. : 280-288

Spandidos Publications

Access to resources Recommend Favorite

Impact of immunosuppressive agents on the expression of indoleamine 2,3-dioxygenase, heme oxygenase-1 and interleukin-7 in mesangial cells

By                      

Molecular Medicine Reports, Vol. 12, Iss. 2, 2015-01 ,pp. : 2577-2583

Spandidos Publications

Access to resources Recommend Favorite

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell–based cancer vaccination

By Galea-Lauri Joanna   Wells James   Darling David   Harrison Phillip   Farzaneh Farzin  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 11, 2004-11 ,pp. : 963-977

Springer Publishing Company

Access to resources Recommend Favorite

Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells

By El Kholy Noura  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 270-278

Humana Press, Inc

Access to resources Recommend Favorite